Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

  1. Kong, A.
  2. Rea, D.
  3. Ahmed, S.
  4. Beck, J.T.
  5. López, R.L.
  6. Biganzoli, L.
  7. Armstrong, A.C.
  8. Aglietta, M.
  9. Alba, E.
  10. Campone, M.
  11. Schmitz, S.-F.H.
  12. Lefebvre, C.
  13. Akimov, M.
  14. Lee, S.-C.
Revue:
Oncotarget

ISSN: 1949-2553

Année de publication: 2016

Volumen: 7

Número: 25

Pages: 37680-37692

Type: Article

DOI: 10.18632/ONCOTARGET.8974 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus